| | FDA/CFSAN Letter to Reiterate Certain Public Health and Safety Concerns to Firms Manufacturing or Importing Dietary ... (Site not responding. Last check: 2007-10-08) |
 | | FDA strongly recommends that firms should consider the public health consequences of this disease in taking whatever steps are necessary to assure themselves and the public that such ingredients do not come from cattle born, raised, or slaughtered in countries where BSE exists. |
 | | While transmission of the causative agent of BSE to humans has not been definitively documented to date, inter-species transfer has been demonstrated (e.g., mice can be infected by exposure to infected bovine tissues). |
 | | Although there is still no definitive evidence that the consumption of bovine tissues that contain the transmissible agent for BSE cause CJD in humans, FDA is concerned that appropriate measures to eliminate the use of bovine tissues from BSE-countries be instituted by firms that use bovine-derived ingredients in their products. |
| vm.cfsan.fda.gov /~dms/dspltr05.html (690 words) |